Wednesday, April 5, 2017

Leukemia - Table of Contents alert Volume 31 Issue 4

If you are unable to see the message below, click here to view.

Nature Reviews Immunology and Nature Reviews Molecular Cell Biology: Poster on Bone marrow niches and HSC fates

This poster shows the signalling pathways between stromal and haematopoietic cells of the bone marrow niche that direct the fate of haematopoietic stem cells. 


Produced with support from 
STEMCELL Technologies


Volume 31, Issue 4 (April 2017)

In this issue
Original Articles
Letters to the Editor

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter



Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors

I Aldoss, R C Bargou, D Nagorsen, G R Friberg, P A Baeuerle and S J Forman

Leukemia 2017 31: 777-787; advance online publication, December 28, 2016; 10.1038/leu.2016.391

Abstract | Full Text

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders

P Valent, K Sotlar, K Blatt, K Hartmann, A Reiter, I Sadovnik, W R Sperr, P Bettelheim, C Akin, K Bauer, T I George, E Hadzijusufovic, D Wolf, J Gotlib, F-X Mahon, D D Metcalfe, H-P Horny and M Arock

Leukemia 2017 31: 788-797; advance online publication, January 16, 2017; 10.1038/leu.2017.15

Abstract | Full Text

Biological and clinical consequences of NPM1 mutations in AML

E M Heath, S M Chan, M D Minden, T Murphy, L I Shlush and A D Schimmer

Leukemia 2017 31: 798-807; advance online publication, January 23, 2017; 10.1038/leu.2017.30

Abstract | Full Text

Original Articles



Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia

N Narayan, L Morenos, B Phipson, S N Willis, G Brumatti, S Eggers, N Lalaoui, L M Brown, H J Kosasih, R C Bartolo, L Zhou, D Catchpoole, R Saffery, A Oshlack, G J Goodall and P G Ekert

Leukemia 2017 31: 808-820; advance online publication, October 14, 2016; 10.1038/leu.2016.279

Abstract | Full Text


Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences

E Waanders, B Scheijen, M C J Jongmans, H Venselaar, S V van Reijmersdal, A H A van Dijk, A Pastorczak, R D A Weren, C E van der Schoot, M van de Vorst, E Sonneveld, N Hoogerbrugge, V H J van der Velden, B Gruhn, P M Hoogerbrugge, J J M van Dongen, A Geurts van Kessel, F N van Leeuwen and R P Kuiper

Leukemia 2017 31: 821-828; advance online publication, October 13, 2016; 10.1038/leu.2016.277

Abstract | Full Text


Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

C Schütz, S Inselmann, S Sausslele, C T Dietz, M C Mu¨ller, E Eigendorff, C A Brendel, S K Metzelder, T H Bru¨mmendorf, C Waller, J Dengler, M E Goebeler, R Herbst, G Freunek, S Hanzel, T Illmer, Y Wang, T Lange, F Finkernagel, R Hehlmann, M Huber, A Neubauer, A Hochhaus, J Guilhot, F Xavier Mahon, M Pfirrmann and A Burchert

Leukemia 2017 31: 829-836; advance online publication, January 11, 2017; 10.1038/leu.2017.9

Abstract | Full Text


Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia

B Stamatopoulos, A Timbs, D Bruce, T Smith, R Clifford, P Robbe, A Burns, D V Vavoulis, L Lopez, P Antoniou, J Mason, H Dreau and A Schuh

Leukemia 2017 31: 837-845; advance online publication, October 31, 2016; 10.1038/leu.2016.307

Abstract | Full Text


High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) OPEN

K Fritsch, B Kasenda, E Schorb, P Hau, J Bloehdorn, R Möhle, S Löw, M Binder, J Atta, U Keller, H-H Wolf, S W Krause, G Heß, R Naumann, S Sasse, C Hirt, M Lamprecht, U Martens, A Morgner, J Panse, N Frickhofen, A Röth, C Hader, M Deckert, H Fricker, G Ihorst, J Finke and G Illerhaus

Leukemia 2017 31: 846-852; advance online publication, November 15, 2016; 10.1038/leu.2016.334

Abstract | Full Text


The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma

S Manier, J T Powers, A Sacco, S V Glavey, D Huynh, M R Reagan, K Z Salem, M Moschetta, J Shi, Y Mishima, C Roche-Lestienne, X Leleu, A M Roccaro, G Q Daley and I M Ghobrial

Leukemia 2017 31: 853-860; advance online publication, October 24, 2016; 10.1038/leu.2016.296

Abstract | Full Text


Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome

N Hasegawa, M Oshima, G Sashida, H Matsui, S Koide, A Saraya, C Wang, T Muto, K Takane, A Kaneda, K Shimoda, C Nakaseko, K Yokote and A Iwama

Leukemia 2017 31: 861-871; advance online publication, October 3, 2016; 10.1038/leu.2016.268

Abstract | Full Text

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy

G L Uy, E J Duncavage, G S Chang, M A Jacoby, C A Miller, J Shao, S Heath, K Elliott, T Reineck, R S Fulton, C C Fronick, M O'Laughlin, L Ganel, C N Abboud, A F Cashen, J F DiPersio, R K Wilson, D C Link, J S Welch, T J Ley, T A Graubert, P Westervelt and M J Walter

Leukemia 2017 31: 872-881; advance online publication, October 14, 2016; 10.1038/leu.2016.282

Abstract | Full Text


Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations

M Marchetti, G Barosi, F Cervantes, G Birgegård, M Griesshammer, C Harrison, R Hehlmann, J-J Kiladjian, N Kröger, M F McMullin, F Passamonti, A Vannucchi and T Barbui

Leukemia 2017 31: 882-888; advance online publication, October 14, 2016; 10.1038/leu.2016.283

Abstract | Full Text

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis

R F Schlenk, F Stegelmann, A Reiter, E Jost, N Gattermann, H Hebart, C Waller, A Hochhaus, U Platzbecker, P Schafhausen, I W Blau, W Verbeek, F H Heidel, M Werner, H Kreipe, V Teleanu, A Benner, H Döhner, M Grießhammer and K Döhner

Leukemia 2017 31: 889-895; advance online publication, October 24, 2016; 10.1038/leu.2016.299

Abstract | Full Text

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence OPEN

A Tefferi, H K Al-Ali, G Barosi, T Devos, H Gisslinger, Q Jiang, J-J Kiladjian, R Mesa, F Passamonti, V Ribrag, G Schiller, A M Vannucchi, D Zhou, D Reiser, J Zhong and R P Gale for the RESUME trialists

Leukemia 2017 31: 896-902; advance online publication, October 24, 2016; 10.1038/leu.2016.300

Abstract | Full Text


Pre-transplant donor CD4 invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease

M-T Rubio, M Bouillié, N Bouazza, T Coman, H Trebeden-Nègre, A Gomez, F Suarez, D Sibon, A Brignier, E Paubelle, S Nguyen-Khoc, M Cavazzana, O Lantz, M Mohty, S Urien and O Hermine

Leukemia 2017 31: 903-912; advance online publication, October 14, 2016; 10.1038/leu.2016.281

Abstract | Full Text


MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia

B Xu, Y Zhao, X Wang, P Gong and W Ge

Leukemia 2017 31: 913-921; advance online publication, October 24, 2016; 10.1038/leu.2016.297

Abstract | Full Text


Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS

E Müller, S Bauer, T Stühmer, A Mottok, C-J Scholz, T Steinbrunn, D Brünnert, A Brandl, H Schraud, S Kreßmann, A Beilhack, A Rosenwald, R C Bargou and M Chatterjee

Leukemia 2017 31: 922-933; advance online publication, September 30, 2016; 10.1038/leu.2016.264

Abstract | Full Text

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation OPEN

K Kollmann, W Warsch, C Gonzalez-Arias, F L Nice, E Avezov, J Milburn, J Li, D Dimitropoulou, S Biddie, M Wang, E Poynton, M Colzani, M R Tijssen, S Anand, U McDermott, B Huntly and T Green

Leukemia 2017 31: 934-944; advance online publication, October 14, 2016; 10.1038/leu.2016.280

Abstract | Full Text

Estrogen promotes megakaryocyte polyploidization via estrogen receptor beta-mediated transcription of GATA1

C Du, Y Xu, K Yang, S Chen, X Wang, S Wang, C Wang, M Shen, F Chen, M Chen, D Zeng, F Li, T Wang, F Wang, J Zhao, G Ai, T Cheng, Y Su and J Wang

Leukemia 2017 31: 945-956; advance online publication, October 17, 2016; 10.1038/leu.2016.285

Abstract | Full Text

Transcriptional regulation of SPROUTY2 by MYB influences myeloid cell proliferation and stem cell properties by enhancing responsiveness to IL-3

M Clarke, G Volpe, L Sheriff, D Walton, C Ward, W Wei, S Dumon, P García and J Frampton

Leukemia 2017 31: 957-966; advance online publication, October 17, 2016; 10.1038/leu.2016.289

Abstract | Full Text

Letters to the Editor


Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma

J Bordini, S Galvan, M Ponzoni, M T S Bertilaccio, M Chesi, P L Bergsagel, C Camaschella and A Campanella

Leukemia 2017 31: 967-970; advance online publication, November 24, 2016; 10.1038/leu.2016.346

Full Text

Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients

F Passamonti, B Mora, T Giorgino, P Guglielmelli, M Cazzola, M Maffioli, A Rambaldi, M Caramella, R Komrokji, J Gotlib, J J Kiladjian, F Cervantes, T Devos, F Palandri, V De Stefano, M Ruggeri, R Silver, G Benevolo, F Albano, D Caramazza, E Rumi, M Merli, D Pietra, R Casalone, T Barbui, L Pieri and A M Vannucchi

Leukemia 2017 31: 970-973; advance online publication, November 25, 2016; 10.1038/leu.2016.351

Full Text

NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group

V Bisio, M Zampini, C Tregnago, E Manara, V Salsi, A Di Meglio, R Masetti, M Togni, D Di Giacomo, S Minuzzo, A Leszl, V Zappavigna, R Rondelli, C Mecucci, A Pession, F Locatelli, G Basso and M Pigazzi

Leukemia 2017 31: 974-977; advance online publication, November 28, 2016; 10.1038/leu.2016.361

Full Text

Baboon envelope pseudotyped lentiviral vectors: a highly efficient new tool to genetically manipulate T-cell acute lymphoblastic leukaemia-initiating cells

C Costa, G Hypolite, O Bernadin, C Lévy, F-L Cosset, V Asnafi, E Macintyre, E Verhoeyen and M Tesio

Leukemia 2017 31: 977-980; advance online publication, December 6, 2016; 10.1038/leu.2016.372

Full Text

High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL

S K Tasian, C Hurtz, G B Wertheim, N G Bailey, M S Lim, R C Harvey, I-M Chen, C L Willman, R Astles, A Zebrowski, S C Reshmi, M M Li, N V Frey, S M Luger, M Carroll and A E Perl

Leukemia 2017 31: 981-984; advance online publication, December 9, 2016; 10.1038/leu.2016.375

Full Text

CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D

H Bruns, M Böttcher, M Qorraj, M Fabri, S Jitschin, J Dindorf, L Busch, R Jitschin, A Mackensen and D Mougiakakos

Leukemia 2017 31: 985-988; advance online publication, December 23, 2016; 10.1038/leu.2016.378

Full Text

Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients

D Rossille, I Azzaoui, A L Feldman, M J Maurer, G Labouré, M Parrens, C Pangault, T M Habermann, S M Ansell, B K Link, K Tarte, T E Witzig, T Lamy, S L Slager, M Roussel, N Milpied, J R Cerhan and T Fest

Leukemia 2017 31: 988-991; advance online publication, January 27, 2017; 10.1038/leu.2016.385

Full Text

PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma

S Panchabhai, I Schlam, S Sebastian and R Fonseca

Leukemia 2017 31: 991-994; advance online publication, December 27, 2016; 10.1038/leu.2016.389

Full Text

HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia

P Mehdipour, F Santoro, O A Botrugno, M Romanenghi, C Pagliuca, G M Matthews, R W Johnstone and S Minucci

Leukemia 2017 31: 995-997; advance online publication, January 24, 2017; 10.1038/leu.2017.3

Full Text

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study OPEN

H Ludwig, K Weisel, M T Petrucci, X Leleu, A M Cafro, L Garderet, C Leitgeb, R Foa, R Greil, I Yakoub-Agha, D Zboralski, S Vauléon, T Dümmler, D Beyer, A Kruschinski, K Riecke, M Baumann and M Engelhardt

Leukemia 2017 31: 997-1000; advance online publication, January 11, 2017; 10.1038/leu.2017.5

Full Text

Gain of function in Jak2V617F-positive T-cells

G Nishanth, D Wolleschak, C Fahldieck, T Fischer, A Mullally, F Perner, T M Schnöder, S Just, F H Heidel and D Schlüter

Leukemia 2017 31: 1000-1003; advance online publication, January 11, 2017; 10.1038/leu.2017.6

Full Text

Myelodysplastic syndromes and bone loss in mice and men

H Weidner, M Rauner, F Trautmann, J Schmitt, E Balaian, A Mies, S Helas, U Baschant, C Khandanpour, M Bornhäuser, L C Hofbauer and U Platzbecker

Leukemia 2017 31: 1003-1007; advance online publication, January 11, 2017; 10.1038/leu.2017.7

Full Text

Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL

V Serafin, V Lissandron, B Buldini, S Bresolin, M Paganin, F Grillo, N Andriano, C Palmi, G Cazzaniga, S Marmiroli, V Conter, G Basso and B Accordi

Leukemia 2017 31: 1007-1011; advance online publication, January 13, 2017; 10.1038/leu.2017.13

Full Text

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group

N Jahn, M Agrawal, L Bullinger, D Weber, A Corbacioglu, V I Gaidzik, L Schmalbrock, F Thol, M Heuser, J Krauter, G Göhring, A Kündgen, W Fiedler, M Wattad, G Held, C-H Köhne, H-A Horst, M Lübbert, A Ganser, R F Schlenk, H Döhner, K Döhner and P Paschka

Leukemia 2017 31: 1012-1015; advance online publication, January 16, 2017; 10.1038/leu.2017.18

Full Text

Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence

M Baccarani

Leukemia 2017 31: 1015-1016; advance online publication, February 3, 2017; 10.1038/leu.2017.20

Full Text



Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein depletion

D Fahrenkamp, O Herrmann, S Koschmieder, T H Brümmendorf and M Schemionek

Leukemia 2017 31: 1017-1019; advance online publication, February 7, 2017; 10.1038/leu.2017.19

Full Text

Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation

S Kobayashi, A Kobayashi, Y Osawa, S Nagao, K Takano, Y Okada, N Tachi, M Teramoto, T Kawamura, T Horiuchi, S Kato, T Maekawa, T Yamamura, J Watanabe, Y Harada, H Harada, K Sato and F Kimura

Leukemia 2017 31: 1020-1022; advance online publication, February 14, 2017; 10.1038/leu.2017.44

Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

nature publishing group

No comments: